References
- Antonio Palumbo, Kenneth Anderson (2011). Multiple Myeloma. N Engl J Med, 364, 1046-60. https://doi.org/10.1056/NEJMra1011442
- Basit A, Siddiqui N, Hameed A, et al (2014). Factors affecting outcome of patients with multiple myeloma. J Ayub Med Coll Abottabad, 26, 376-9.
- Dimopoulos MA, Kastritis E, Michalis E, et al (2012). The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. Ann Oncol, 23, 722-9. https://doi.org/10.1093/annonc/mdr276
- Diwan AG, Gandhi SA, Krishna K, Shinde VP (2014). Clinical profile of the spectrum of multiple myeloma in a teaching hospital. Med J DY Patil Univ, 7, 185-8. https://doi.org/10.4103/0975-2870.126335
- Eriksson M, Karisson M (1992). Occupational and other environ mental factors and multiple niycolma: a population based case-control study. Br1 Ind Med, 49, 95-103.
- El Husseiny NM, Kasem N, El Azeeim HA, Mattar MW (2014). Multiple myeloma: a descriptive study of 217 Egyptian patients. Ann Hematol, 93, 141-5. https://doi.org/10.1007/s00277-013-1849-3
- Greipp PR, San Miguel J, Durie BG, et al (2005). International staging system for multiple myeloma. J ClinOncol, 23, 3412-20. https://doi.org/10.1200/JCO.2005.04.242
- Inam U, Raziq F, Tahir M, Wazir R, Rafiq A (2010). Hematological presentation of multiple myeloma in Khyber Pakhtunkhwa. Gomal J Med Sci, 8, 130-3.
- Kadar K, Wolf K, Tabori J, Karadi I, Varkonyi J (2012). The albumin and monoclonal protein ratio as prognostic marker for multiple myeloma in the era of novel agents. Pathol Oncol Res, 18, 557-61. https://doi.org/10.1007/s12253-012-9506-z
- Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc, 78, 21-33. https://doi.org/10.4065/78.1.21
- McKenna RW, Kyle RA, Kuehl WM, et al (2008). WHO classification of tumours of haemopoietic and lymphoid tissues. Lyon: International agency for research on cancer, 202.
- Mehdi WA, Zainulabdeen JA, Mehde AA (2013). Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev, 14, 3663-7. https://doi.org/10.7314/APJCP.2013.14.6.3663
- Mansoor S, Siddiqui I, Adil S, Kakapeto GN, Fatmi Z (2005). Frequency of hypercalcemia in patients of multiple myeloma in Karachi. J Coll Physicians Surg Pak, 15, 409-12.
- Rajkumar SV (2011). Treatment of multiple myeloma. Nat Rev Clin Oncol, 8, 479-91. https://doi.org/10.1038/nrclinonc.2011.63
- Shaheen H, Ghanghroo I, Malik I (1999). Clinicopathological features and management of Pakistani patients with multiple myeloma. J Pak Med Assoc, 4, 233-7.
- Sashidharan N, Shenoy S, Kishore MK, Thanusubramanian H (2015). Comparison of two therapeutic regimes, lenalidomide with dexamethasone and thalidomide with dexamethasone, in the treatment of multiple myeloma at a tertiary care hospital in India. J Clin Diagn Res, 9, 1-4. https://doi.org/10.1111/crj.12091
- Sun JJ, Zhang C, Zhou J, Yang HL (2015). Pooled analysis of pomalidomide for treating patients with multiple myeloma. Asian Pac J Cancer Prev, 16, 3163-6. https://doi.org/10.7314/APJCP.2015.16.8.3163
- Sutandyo N, Firna E, Agustina J, et al (2015).Clinicopathology profile and bone involvement of multiple myeloma patients in Dharmais National Cancer Hospital, Indonesia. Asian Pac J Cancer Prev, 16, 6261-5. https://doi.org/10.7314/APJCP.2015.16.15.6261
- Subramanian R, Basu D, Dutta TK (2009). Prognostic significance of bone marrow histology in multiple myeloma. Indian J Cancer, 46, 40-5. https://doi.org/10.4103/0019-509X.48594
- Vincent Rajkumar S (2014). Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol, 89, 999-1009.
- Wang L, Wang KF, Chang BY, Chen XQ, Xia ZJ (2015). Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev, 16, 2093-8. https://doi.org/10.7314/APJCP.2015.16.5.2093
- Younes M, Hachfi H, Hammouda F, Younes K, et al (2014). Survival prognosis factors in multiple myeloma. Tunis Med, 92, 399-40.